regulatory
confidence high
sentiment positive
materiality 0.60
FDA accepts IND for first neoantigen-directed T-cell therapy from Adaptive-Genentech collaboration
Adaptive Biotechnologies Corp
- FDA accepted IND for TCR-based T-cell therapy candidate; first from collaboration to enter clinical development.
- Therapy targets neoantigens identified via Adaptive's TCR discovery platform.
- Genentech responsible for clinical, regulatory, and commercialization efforts.
- Adaptive reaffirms FY2023 revenue guidance of $205-215 million.